Tabrecta (Capmatinib)
- Medicine Name: Tabrecta
- Generic Name: Capmatinib
- Dosage Form & Strength: Tablets: 150/200 mg
- Manufactured By: Novartis Pharma Corporation
Tabrecta is a kinase inhibitor used for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET (Mesenchymal-Epithelial Transition) exon-14 skipping.
Recommended Dosage: The recommended dosage is 400 mg orally twice daily with or without food. Swallow the tablets of Tabrecta whole, without breaking, crushing or chewing. In case a patient misses or vomits any dose, instruct the patient not to make up the dose, but to take the very next dose at its scheduled time.
- ILD/pneumonitis, which can be fatal, developed in patients treated with tabrecta tablet 200 mg. Monitor for new or worsening pulmonary signs and symptoms indicative of ILD/pneumonitis (e.g., cough, dyspnea, fever).
- Hepatotoxicity appeared in patients treated with Tabrecta (Capmatinib Tablets). Monitor liver function tests (including ALT, AST, and total bilirubin) before starting Capmatinib, every 2 weeks during the initial 3 months of treatment, then monthly or as clinically indicated, with a bit more frequent testing in those who develop increased bilirubin or transaminases.
- On behalf of findings from animal studies and its mechanism of action, capmatinib 150mg can cause fetal harm if used by a pregnant woman. Advise males with female partners of reproductive age to use apt contraception during while on treatment and for 7 days after the last dose.
- On behalf of findings from animal studies, there is a potential risk of photosensitivity reactions with capmatinib 200 mg tablets. Advise patients to limit direct ultraviolet exposure while on therapy with Capmatinib.
What documents are required to import TABRECTA to India?
TABRECTA (Capmatinib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is TABRECTA available in India?
TABRECTA (capmatinib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India ( Kolkata, Hyderabad, Mumbai, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
TABRECTA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of TABRECTA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for tabrecta price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the TABRECTA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Tabrecta®?
Capmatinib is Generic Name for the trade name drug Tabrecta®.
What is the Manufacturer Name of Tabrecta®?
Tabrecta® is manufactured by Novartis Pharmaceuticals Corporation.
Is Tabrecta® approved by the FDA?
Yes, Tabrecta® is approved by the FDA. Date of approval: May 6, 2020.
What is Tabrecta®?
Tabrecta (capmatinib) is an FDA approved medicine to treat adult patients with non-small cell lung cancer (NSCLC) that has progressed to other parts of the body.
What is the dosage and form of Tabrecta® supplied?
Tabrecta® is supplied as Tablets: 150/200 mg for oral administration.
What are the most common side effects due to Tabrecta®?
Most common side effects due to Tabrecta® include: nausea, peripheral edema, fatigue, dyspnea, vomiting, and decreased appetite.
How much does Tabrecta® cost in India?
Tabrecta (capmatinib) cost in India is sensibly reasonable.
In order to procure this metastatic non-small cell lung cancer (NSCLC) medicine authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Tabrecta®?
Dispense the tablets in the original package with the desiccant cartridge. Store at 20-25°C (68-77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from the moisture.
What are the Highlights of prescribing information for Tabrecta®?
Click Here to download full Tabrecta prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.